The ZNF217 biomarker predicts low-and high-risk oncotype DX® recurrence score in ER-positive invasive breast cancers

Pascale A. Cohen; Olivier Loudig; Christina Liu; Joseph Albanese; Susan Fineberg

doi:10.3389/fphar.2019.00524

The ZNF217 biomarker predicts low-and high-risk oncotype DX® recurrence score in ER-positive invasive breast cancers

Pascale A. Cohen
, Olivier Loudig
, Christina Liu
, Joseph Albanese
, Susan Fineberg

Center for Discovery and Innovation

Hackensack Meridian School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	524
Journal	Frontiers in Pharmacology
Volume	10
Issue number	MAY
DOIs	https://doi.org/10.3389/fphar.2019.00524
State	Published - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Keywords

Biomarker
Breast cancer
Estrogen-receptor positive
Expression
Oncotype DX®
ZNF217

Access to Document

10.3389/fphar.2019.00524

Cite this

@article{fdcb395331ff4e64b15bda44e9da4b67,

title = "The ZNF217 biomarker predicts low-and high-risk oncotype DX{\textregistered} recurrence score in ER-positive invasive breast cancers",

keywords = "Biomarker, Breast cancer, Estrogen-receptor positive, Expression, Oncotype DX{\textregistered}, ZNF217",

author = "Cohen, \{Pascale A.\} and Olivier Loudig and Christina Liu and Joseph Albanese and Susan Fineberg",

year = "2019",

doi = "10.3389/fphar.2019.00524",

language = "English",

volume = "10",

journal = "Frontiers in Pharmacology",

issn = "1663-9812",

publisher = "Frontiers Media SA",

number = "MAY",

}

TY - JOUR

T1 - The ZNF217 biomarker predicts low-and high-risk oncotype DX® recurrence score in ER-positive invasive breast cancers

AU - Cohen, Pascale A.

AU - Loudig, Olivier

AU - Liu, Christina

AU - Albanese, Joseph

AU - Fineberg, Susan

PY - 2019

Y1 - 2019

KW - Biomarker

KW - Breast cancer

KW - Estrogen-receptor positive

KW - Expression

KW - Oncotype DX®

KW - ZNF217

UR - https://www.scopus.com/pages/publications/85068864244

U2 - 10.3389/fphar.2019.00524

DO - 10.3389/fphar.2019.00524

M3 - Article

SN - 1663-9812

VL - 10

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

IS - MAY

M1 - 524

ER -

The ZNF217 biomarker predicts low-and high-risk oncotype DX® recurrence score in ER-positive invasive breast cancers

UN SDGs

ASJC Scopus subject areas

Keywords

Access to Document

Other files and links

Cite this